Biomed Lublin Wytwornia Surowic I Szczepionek SA logo

BML - Biomed Lublin Wytwornia Surowic I Szczepionek SA Share Price

PLN9.04 0.0  0.0%

Last Trade - 01/03/21

Sector
Healthcare
Size
Small Cap
Market Cap ÂŁ107.5m
Enterprise Value ÂŁ109.9m
Revenue ÂŁ7.79m
Position in Universe 165th / 790
Bullish
Bearish
Unlock BML Revenue
Momentum
Relative Strength (%)
1m -1.70%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -72.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
33.6 42.6 36.3 31.4 32.3 39.1 +3.1%
-78.0
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, BiomedLublin Wytwornia Surowic i Szc SA revenues increased 6% toPLN28M. Net income decreased 15% to PLN813K. Revenuesreflect Onco BCG segment increase from PLN1.5M to PLN3.8M,Lakcid segment increase of 50% to PLN4.8M, Other Countriessegment increase of 32% to PLN10.7M, European Union(Region) segment increase of 78% to PLN1.3M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BML
Graphical History

Revenue

BML Revenue Unlock BML Revenue

Net Income

BML Net Income Unlock BML Revenue

Normalised EPS

BML Normalised EPS Unlock BML Revenue

PE Ratio Range

BML PE Ratio Range Unlock BML Revenue

Dividend Yield Range

BML Dividend Yield Range Unlock BML Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BML EPS Forecasts Unlock BML Revenue
Profile Summary

Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company engaged in the pharmaceuticals industry.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated December 13, 2010
Public Since July 29, 2011
No. of Shareholders: n/a
No. of Employees: 230
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Warsaw Stock Exchange
Shares in Issue 62,260,410
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BML Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BML
Upcoming Events for BML
Frequently Asked Questions for Biomed Lublin Wytwornia Surowic i Szczepionek SA
What is the Biomed Lublin Wytwornia Surowic i Szczepionek SA share price?

As of 01/03/21, shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA are trading at PLN9.04, giving the company a market capitalisation of ÂŁ107.5m. This share price information is delayed by 15 minutes.

How has the Biomed Lublin Wytwornia Surowic i Szczepionek SA share price performed this year?

Shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA are currently trading at PLN9.04 and the price has moved by 0.577k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biomed Lublin Wytwornia Surowic i Szczepionek SA price has moved by 0.538k% over the past year.

What are the analyst and broker recommendations for Biomed Lublin Wytwornia Surowic i Szczepionek SA?

There are no analysts currently covering Biomed Lublin Wytwornia Surowic i Szczepionek SA.

When will Biomed Lublin Wytwornia Surowic i Szczepionek SA next release its financial results?

Biomed Lublin Wytwornia Surowic i Szczepionek SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Biomed Lublin Wytwornia Surowic i Szczepionek SA dividend yield?

Biomed Lublin Wytwornia Surowic i Szczepionek SA does not currently pay a dividend.

Does Biomed Lublin Wytwornia Surowic i Szczepionek SA pay a dividend?

Biomed Lublin Wytwornia Surowic i Szczepionek SA does not currently pay a dividend.

When does Biomed Lublin Wytwornia Surowic i Szczepionek SA next pay dividends?

Biomed Lublin Wytwornia Surowic i Szczepionek SA does not currently pay a dividend.

How do I buy Biomed Lublin Wytwornia Surowic i Szczepionek SA shares?

To buy shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biomed Lublin Wytwornia Surowic i Szczepionek SA?

Shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA are currently trading at PLN9.04, giving the company a market capitalisation of ÂŁ107.5m.

Where are Biomed Lublin Wytwornia Surowic i Szczepionek SA shares listed? Where are Biomed Lublin Wytwornia Surowic i Szczepionek SA shares listed?

Here are the trading details for Biomed Lublin Wytwornia Surowic i Szczepionek SA:

Country of listing: Poland
Exchange: WSE
Ticker Symbol: BML
What kind of share is Biomed Lublin Wytwornia Surowic i Szczepionek SA?

Based on an overall assessment of its quality, value and momentum, Biomed Lublin Wytwornia Surowic i Szczepionek SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biomed Lublin Wytwornia Surowic i Szczepionek SA share price forecast 2021?

We were not able to load any forecast data for Biomed Lublin Wytwornia Surowic i Szczepionek SA.

How can I tell whether the Biomed Lublin Wytwornia Surowic i Szczepionek SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomed Lublin Wytwornia Surowic i Szczepionek SA. Over the past six months, the relative strength of its shares against the market has been -56.82%. At the current price of PLN9.04, shares in Biomed Lublin Wytwornia Surowic i Szczepionek SA are trading at -28.29% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biomed Lublin Wytwornia Surowic i Szczepionek SA PE Ratio?

The Biomed Lublin Wytwornia Surowic i Szczepionek SA PE ratio based on its reported earnings over the past 12 months is 0.302k. The shares are currently trading at PLN9.04.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Biomed Lublin Wytwornia Surowic i Szczepionek SA?

Biomed Lublin Wytwornia Surowic i Szczepionek SA's management team is headed by:

Waldemar Sierocki - SEC
Wiktor Napiora - VSU
Dariusz Kucowicz - SUB
Jaroslaw Blaszczak - CSU
Katarzyna Krukowska - CAO
Piotr Kwasniewski - SUB
Konrad Miterski - IND
Piotr Fic - CMG
Dirk Pamperin - IND
Who are the major shareholders of Biomed Lublin Wytwornia Surowic i Szczepionek SA?

Here are the top five shareholders of Biomed Lublin Wytwornia Surowic i Szczepionek SA based on the size of their shareholding:

Kucowicz (Dariusz) Individual Investor
Percentage owned: 8.95% (5.57m shares)
Organizacja Polskich Dystrybutorow Farmaceutycznych SA Corporation
Percentage owned: 8.14% (5.07m shares)
Napiora (Wiktor) Individual Investor
Percentage owned: 7.91% (4.92m shares)
Sierocki (Przemyslaw Zbigniew) Individual Investor
Percentage owned: 7.69% (4.79m shares)
Sierocki (Waldemar Artur) Individual Investor
Percentage owned: 7.69% (4.79m shares)
Similar to BML
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.